Category: Melanoma Doctors

Maurie Markman MD or, as I refer to him, “M&M” understands what counts. What’s that, you ask? It’s the value of “reassurance” given to a patient following a “positive” or “negative” test result that suggests either the absence or lack of progression of a cancer, independent of any objective population-based clinical trial evidence that such…

WEBINAR.  Title: PD1 Therapy Update Date: Friday, November 30, 2012 Time: 11:30 AM – 12:30 PM EST  Listen the Toni – He’s the Man! http://campaign.r20.constantcontact.com/render?llr=vza98ecab&v=001KdaRoZmLBVwh7NHbQlfiK7zO8HP9YmnIGhzjQDp1fm2kYnfzZj6aHnklGwzFkSoQCpP_Oec_JvKYsh6kwa1w-ZgJe0U8luR-QqIq2AJJV9ln-HFTV4Y3mFrSdZHlquI9ZxXddGLsaqUPLiMAVzUs7A%3D%3D  

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses a phase I/II trial examining the combination of two investigational targeted therapies for patients with BRAF-mutated melanoma. Kris believes this trial showcases the changes taking place in cancer care, as a result of the molecular revolution. Traditionally, adding two…

Every year more than 53,000 people in the United States are diagnosed with melanoma, making it the fastest growing cancer both in the United States and worldwide, especially among young adults between the ages of 20 and 30 years. While melanoma is treatable when detected in the early stages, it causes almost 8,000 deaths annually.…

Antoni Ribas UCLA melanoma – Dr. Ribas is a physician-scientist conducting laboratory and clinical research focused in malignant melanoma. His research includes: laboratory and clinical translational research in adoptive cell transfer therapy with T-cell receptor (TCR) engineered lymphocytes understanding the antitumor activity of CTLA4-blocking antibodies molecular imaging and advanced immune monitoring for the study of…